McKinsey
The risks and challenges of the global COVID-19-vaccine rollout
Gaurav Agrawal, partner in McKinsey’s New York office; Tara Azimi, partner in the Washington, DC, office; Jennifer Heller and Parag Patel, partners in the Chicago office, Adam Sabow is a senior partner n the Chicago office; Pooja Kumar, partner in the Philadelphia office; Mihir Mysore, a partner in the Houston office; Shubham Singhal, a senior partner in the Detroit office; and Joseph Truesdale, associate partner in the Boston office.
6 comments:
The risks are... failing to make enormous profit?
Merck cancelled theirs:
https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates/
Now increasing mRNA purchases:
https://www.washingtonpost.com/health/2021/01/26/vaccine-supply-biden/
Universities should be doing the research and development, not these for-profit private corporations.
Pfizer, for example, runs a criminal enterprise on the side. This is not hyperbole. What would you call illegal off-label marketing of drugs?
^ Import Export business.
(Unless you find a bank that will help you in the laundering of your export).
Post a Comment